Stay updated on Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial

Sign up to get notified when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The record now presents details for the completed ALPHA phase II study of afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma, including its eligibility criteria, treatment plan, outcomes, and publication.
    Difference
    44%
    Check dated 2026-11-08T01:26:37.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-31T19:39:09.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A banner announces updates to NIH terminology, including a transition from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T21:59:42.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.1 to v3.7.2 while the page continued to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T22:14:50.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T22:13:38.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error page, with the site header and footer visible, indicating restricted access to the content.
    Difference
    18%
    Check dated 2026-09-19T22:20:29.000Z thumbnail image

Stay in the know with updates to Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.